Pfiz­er opts in to net Lian­Bio’s rights to RSV can­di­date, putting down $20M up­front

Pfiz­er and Lian­Bio have had a re­la­tion­ship for over two years now, but the phar­ma’s lat­est move will see it grab a can­di­date from Lian­Bio and pay a pret­ty pen­ny for the priv­i­lege.

On Mon­day, Lian­Bio an­nounced that Pfiz­er has “opt­ed in” to se­cure the rights to sisuna­tovir, an RSV can­di­date in Chi­na, Hong Kong, Macau and Sin­ga­pore, with the deal be­ing un­der Lian­Bio’s ex­ist­ing col­lab­o­ra­tion to ex­pand ac­cess to ther­a­peu­tics in Chi­na. The oral drug is de­signed to in­hib­it the “F-me­di­at­ed fu­sion” with the host cell and is be­ing test­ed to treat RSV in chil­dren and adults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER